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Abstract: Gordon syndrome is a rare inherited monogenic form of hypertension, which is associated 
with hyperkalaemia and metabolic acidosis. Since the recognition of this predominantly autosomal 
dominant condition in the 1960s, the study of families with Gordon syndrome has revealed four 
genes WNK1, WNK4, KLHL3, and CUL3 to be implicated in its pathogenesis after a phenotype–
genotype correlation was realised. The encoded proteins Kelch-like 3 and Cullin 3 interact to form 
a ring-like complex to ubiquitinate WNK-kinase 4, which, in normal circumstances, interacts with 
the sodium chloride co-symporter (NCC), the epithelial sodium channel (ENaC), and the renal outer 
medullary potassium channel (ROMK) in an inhibitory manner to maintain normokalaemia and 
normotension. WNK-kinase 1 has an inhibitory action on WNK-kinase 4. Mutations in WNK1, 
WNK4, KLHL3, and CUL3 all result in the accumulation of WNK-kinase 4 and subsequent 
hypertension, hyperkalaemia, and metabolic acidosis. This review explains the clinical aspects, 
disease mechanisms, and molecular genetics of Gordon syndrome. 
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1. Introduction 
Gordon syndrome, otherwise known as Pseudohypoaldosteronism type 2 
(https://omim.org/phenotypicSeries/PS145260) or familial hyperkalaemia and hypertension 
syndrome, is a rare inherited form of low-renin hypertension associated with hyperkalaemia and 
metabolic acidosis (specifically a type IV renal tubular acidosis) [1–4]. Whilst the glomerular filtration 
rate (GFR) is usually preserved, it can manifest as a particularly severe phenotype with 
hyperkalaemia (serum potassium reaching as high as 8 to 9 mmol/L), resulting in periodic paralysis. 
Gordon syndrome is an interesting outlier amongst other forms of familial hypertension because of 
its hypoaldosterone hyperkalaemia phenotype in contrast with other forms of monogenic 
hypertension, which have normo- or hypokalaemia, thus making serum potassium a useful 
discriminator of the condition [5]. The condition was first described in Australia in the 1960s and was 
named after Richard Gordon after he realised the inherited phenotype by tracking several Australian 
families with the condition [6]. Pedigrees of this syndrome have since been discovered all over the 
world, but the discovery of a distinct phenotype–genotype correlation was made when French 
pedigrees were noted to have much milder manifestations of the condition [7,8]. To date, age of 
diagnosis has varied from (in one researched cohort) 7 months to 39 years and no relationship has 
been found between the severity of biochemistry and age or increase in blood pressure. The 
phenotypic variability includes the degree of sensitivity to a thiazide diuretic, which is the precise 
treatment for this condition and, along with observed pattern of inheritance and linkage studies, 
indicates heterogeneity [9]. No genetic linkage has been found with SLC12A3, which encodes the 
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thiazide sensitive NaCl co-symporter (NCC), in which ‘activating’ mutations would be predicted to 
cause the disease phenotype, given the sensitivity to thiazide diuretics. Most families follow an 
autosomal dominant pattern of inheritance, but recent research has shown some phenotypes of 
Gordon syndrome to be inherited in an autosomal recessive manner [10]. Initially, through linkage 
studies, two loci were identified, the first on chromosome 1 (1q31-q42) (PHA2A), which is still 
unsolved, and chromosome 17 (17p11-q21) (PHA2B). Following this, an intronic deletion was 
detected on chromosome 12 (12p13), which occurred within WNK1 (PHA2C), which, along with 
WNK2/3/4, encodes a family of WNK-kinases [11,12]. WNK4 mutations (PHA2B) were also 
subsequently identified in Gordon syndrome patients. These exonic missense mutations occurred 
within a unique amino acid sequence, ‘the acidic motif’ of WNK4, and resulted in charge-changing 
substitutions but did not affect the kinase activity of WNK4. This ‘acidic motif’ has only made sense 
since the discovery that the WNKs bind to Kelch-like 3 through the acidic motif [12,13]. Lifton’s 
group, using whole exome sequencing, identified two further genes implicated in Gordon syndrome, 
KLHL3 (5q31), which encodes Kelch-like 3 (PHA2D), which was also identified by a French group 
[14], and CUL3 (2q36), which encodes Cullin 3 (PHA2E) [15]. Both of these proteins have been found 
to be involved in the endosomal degradation of WNK4 [16]. Gordon syndrome is therefore a group 
of related disorders, with at least four known monogenic aetiologies. This review will describe the 
clinical presentations and disease mechanisms of known genes implicated in this condition, WNK1, 
WNK4, KLHL3, and CUL3. 
2. Clinical Presentations 
Over 25% of the adult population in the developed world have hypertension [17], which is an 
independent risk factor for myocardial infarction, cerebrovascular disease, and renal failure, and a 
leading cause of morbidity and mortality globally. The kidneys are a major contributing factor to the 
development of hypertension in most cases [18,19]. In total, 5% to 10% of patients with hypertension 
have a secondary cause [20]. Secondary causes should be suspected in patients who have early onset 
hypertension (<30 years old) in the absence of common risk factors, such as obesity. Factors, such as 
resistant hypertension (BP >140/90 despite three or more anti-hypertensive drugs), severe 
hypertension (BP >180/110 or hypertensive emergency), sudden BP increase in a previously stable 
patient, presence of target organ damage, or non-dipping or reverse dipping during 24 h ambulatory 
BP monitoring [21], should also be considered. Essential hypertension is a polygenic disease with 
over 280 genetic variants found to be associated with risk of high blood pressure [22–24]. Monogenic 
forms of secondary hypertension, however, should be suspected in a family history of the disease 
coupled with either low or high serum potassium levels in the presence of supressed renin secretion 
and metabolic alkalosis or acidosis [25]. However, mild hypertension and the absence of electrolyte 
abnormalities do not exclude hereditary conditions and therefore hormonal studies should be 
coupled with genetic testing if a secondary or monogenic cause is suspected. 
Of the monogenic forms of secondary hypertension, most result from increased sodium 
transport along the aldosterone-sensitive distal nephron [26]. Most monogenic forms manifest with 
hypokalaemia, often because the epithelial sodium channel (ENaC) is involved; these mechanisms 
are displayed in Figure 1. Gordon syndrome is also known as Pseudohypoaldosteronism type II as it 
is the only form of monogenic hypertension that manifests as hypoaldosteronism because of 
increased volume expansion, through increased sodium chloride reabsorption in the distal 
convoluted tubule (DCT), which decreases luminal sodium flow in the more distal nephron and 
makes ENaC less functional. Gordon syndrome may manifest with hyperkalaemia partly due to a 
similar way to the downregulation of ENaC by amiloride. Aside from hyperkalaemia and metabolic 
acidosis, a mild hyperchloraemia and calcium leak can be seen (especially with WNK4 mutations), 
which can present as hypercalciuria, hypocalcaemia, low bone mineral density, and renal stones, and 
these findings can precede hypertension [27]. This is evidence that WNK4 positively interacts with 
TRPV5, a calcium resorptive channel [28]. Table 1 highlights the genotype–phenotype correlations in 
Gordon syndrome. The final indicator of a possible diagnosis of Gordon syndrome is the increased 
sensitivity to a thiazide diuretic. This can even cause hypotension, but at an appropriate dose will 
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correct hypertension and all electrolyte abnormalities [8] and therefore once treatment is established, 
risk of cardiovascular disease, cerebrovascular disease, and renal failure is unlikely. Although 
hypertension does increase risk of cerebrovascular accidents, in contrast to glucocorticoid remedial 
hyperaldosteronism, Gordon syndrome does not have a strong association with haemorrhagic stroke. 
Table 2 summarises the differential diagnoses of Gordon syndrome. 
 
 
Figure 1. Molecular mechanisms underlying Gordon syndrome. 
Table 1. Phenotype–genotype correlations in Gordon syndrome. 
 WNK1 WNK4 KLHL3 CUL3 
Hypertension 
Least severe 
phenotype and 
metabolic disorder 
often precedes 
hypertension  
Metabolic disorder 
often precedes 
hypertension 
Recessive mutations are 
more severe and 
diagnosed at an earlier 
age than dominant 
mutations 
Most severe phenotype. 
Presents at youngest 
age (>90% had 
hypertension <age 18. 
Hyperkalaemia Least severe Yes 
Dominant mutations had 
significantly higher 
serum K+ than recessive 
mutations 
Most severe 
Presents at youngest 
age 
Metabolic 
Acidosis 
Least severe Yes Yes Most severe 
Other features  
Hypercalciuria 
Hypocalcaemia 
Decreased bone 
mineral density 
Renal calcium 
stones 
 
Fertility likely affected 
in de novo mutations. 
Growth impairment 
most likely 
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Table 2. Differential diagnosis of Gordon syndrome. 
Diagnosis Genes/Loci Gene Product Inheritance Reason for Hypertension Other Features 
Gordon Syndrome 
1q31-q42 
(Unknown gene) 
17p11-q21 
(WNK4) 
12p13 (WNK1) 
5q31 (KLHL3) 
2q36 (CUL3) 
Mutant WNK-kinase 1, WNK-
kinase 4, Kelch-like 3 or Cullin 
3 
Dominant (can be 
recessive or de 
novo) 
Excessive sodium reabsorption via NCC 
• Hyperkalaemia 
• Hyperchloraemia 
• Metabolic acidosis 
• Very thiazide diuretic sensitive 
Occasionally 
• Hypocalciuria 
• Stones (calcium) 
• Low BMD 
Liddle Syndrome 
16p12.1 
(SCNN1B and 
SCNN1G) 
12p13.31 
(SCNN1A) 
Faulty ENaC (β subunit 
SCNN1B, γ subunit SCNN1G 
or α subunit SCNN1A) 
Dominant Excessive sodium reabsorption by ENaC 
• Hypokalaemia 
• Metabolic alkalosis 
Occasionally 
• Hypernatraemia 
• Early renal failure 
• Early onset stroke 
Congenital Adrenal 
Hyperplasia 
1p12 (HSD3B2) 
6p21 (CYP21A2) 
 
3-β-hydroxysteroid 
dehydrogenase 2 deficiency 
21-hydroxylase deficiency 
 
Recessive 
Excessive ACTH to try to maintain cortisol 
which causes excess mineralocorticoid-like 
hormones which cross react with 
mineralocorticoid receptors 
• Hypokalaemia 
• Metabolic alkalosis 
• Hypocortisolism/high ACTH 
• Ambiguous external genitalia 
• Early development of secondary 
sex characteristics 
• Short stature 
Glucocorticoid Remedial 
Hyperaldosteronism 
8q24 (CYP11B1 
& CYP11B2) 
18-hydroxylase, 11-β 
hydroxylase hybrid gene 
causing aldosterone to be 
under ACTH control 
Dominant Inappropriately high aldosterone levels 
• Hypokalaemia 
• Metabolic alkalosis 
Occasionally 
• Hypernatraemia 
• Increased haemorrhagic stroke 
risk 
Syndrome of Apparent 
Mineralocorticoid Excess 
16q22 
(HSD11B2) 
11-β hydroxysteroid 
dehydrogenase (type 2) 
deficiency 
Recessive 
Defect in ability to metabolise cortisol to 
cortisone resulting in cortisol cross 
reactivity with the mineralocorticoid 
receptor 
• Hypokalaemia 
• Metabolic alkalosis 
• Hypernatraemia 
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Gordon syndrome is a form of monogenic hypertension with a hypoaldosterone phenotype. 
Other forms of monogenic hypertension, including Liddle syndrome, congenital adrenal hyperplasia, 
glucocorticoid remedial hyperaldosteronism, and syndrome of apparent mineralocorticoid excess, 
manifest with hypokalaemia due to hyperstimulation of ENaC in the principal cells of the collecting 
duct in the nephron. Aldosterone interacts with the mineralocorticoid receptor and translocates to 
the nucleus where transcription of ENaC subunits occur, which then populate the apical membrane 
of principal cells. ENaC removes cationic sodium from the lumen, which makes it electronegative. 
This promotes passive potassium secretion from the tubular cell into the lumen via apical ROMK 
channels. Liddle syndrome is caused by missense or frameshift mutations that disrupt the 
organization of the ENaC subunits. This disrupts ENaC from binding to Nedd4-2, a ubiquitin-protein 
ligase, which degrades ENaC, resulting in its increased apical membrane expression and subsequent 
hypokalaemia. Congenital adrenal hyperplasia secondary to mutations in CYP21A2 (which encodes 
21-hydroxylase) results in defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol and 
so cortisol synthesis is reduced. Low cortisol increases ACTH secretion, which increases steroid 
intermediate synthesis, such as deoxycorticosterone (DOC). DOC has potent mineralocorticoid 
action, which stimulates the expression of ENaC, resulting in hypokalaemia. Glucocorticoid remedial 
hyperaldosteronism occurs due chimeric gene changes where the 5-prime regulatory sequences of 
CYP11B1 are fused to the coding region of CYP11B2, which results in ectopic expression of 
aldosterone synthase in the zona fasciculata, resulting in constant stimulation of the 
mineralocorticoid receptor and subsequent increased ENaC expression and hypokalaemia. The 
syndrome of apparent mineralocorticoid excess is caused by a deficiency in 11-β-hydroxysteroid 
dehydrogenase, which results in a defect of the peripheral metabolism of cortisol to cortisone. 
Cortisone excessively cross-reacts at the mineralocorticoid receptor, thereby stimulating ENaC and 
hypokalaemia. 
3. The Regulation of NCC 
Gordon syndrome presents as a biochemical and phenotypic ‘mirror image’ of Gitelman 
syndrome, a salt wasting disease caused by inactivating mutations of SLC12A3 encoding NCC. Most 
of the biochemical defects of Gordon syndrome are corrected by treatment with a thiazide diuretic, 
suggesting that WNK kinases regulate NCC, and this has been confirmed by in vitro studies [29,30]. 
WNK1, WNK3, and WNK4 are all expressed in the kidney. WNK signalling in the kidney controls 
blood pressure and electrolyte homeostasis by managing two opposing aldosterone-controlled 
processes: NaCl reabsorption and potassium excretion in the distal nephron [31]. WNK signalling 
regulates the phosphorylation of and activities of cation-chloride co-transporters (CCCs), which 
include NCC (found in the DCT), KCC4 and NKCC2 (found in the TAL), ROMK, and ENaC (found 
in the DCT and CD). WNKs phosphorylate NCC, NKCC1, and NKCC2 via the phosphorylation and 
activation of SPAK and OSR1 [32–36]. Chloride is regulated via NCC influx and KCC efflux and this 
maintains transepithelial solute and water transport and volume regulation in addition to neuronal 
stimulation. Chloride depletion and cell shrinkage results in WNK phosphorylation of NCC, NKCC1, 
NKCC2, and KCC and the opposite occurs in chloride repletion. It can be concluded that intracellular 
chloride influences whether WNKs have an inhibitory or activatory effect on NCC [37–39]. As WNK4 
is the most sensitive to the chloride of the WNKs, this explains the early postulations in the literature 
that WNK4 was initially inhibitory of NCC as chloride environments were an unrecognised 
confounding factor [40]. 
WNK1 produces two isoforms: L-WNK1 (a longer form) and KS-WNK1 (a shorter kidney specific 
WNK1). KS-WNK1 lacks kinase activity and is only expressed in the distal nephron. Early in vitro 
cell line and Xenopus oocyte studies did not demonstrate a direct effect of WNK1 on NCC, but WNK1 
was shown to abolish WNK4′s inhibitory effect on NCC and phosphorylate SPAK, suggesting an 
important role in NCC regulation [41–44]. More recently, a mouse model of a human WNK1 mutation 
(large deletion of the first intron of WNK1) demonstrated a L-WNK1/SPAK pathway for NCC 
activation. These mice demonstrated a full Gordon syndrome phenotype with increased NCC and 
SPAK expression and phosphorylation in the DCT in addition to an increase in L-WNK1 in the DCT 
Genes 2019, 10, 986 6 of 18 
 
and CD with no change to KS-WNK1 expression [33,45]. Recent studies have shown that WNK4 
becomes active in the presence of KS-WNK1 [46]. WNK3 has a more minor role in the distal nephron 
and activated NCC in a kinase- and SPAK-dependent manner [47,48]. WNK3 knock-out mice have a 
milder phenotype and show a slight blood pressure reduction with salt depletion. In the absence of 
WNK3, NCC phosphorylation is probably maintained by compensatory increased expression of L-
WNK1 [49]. Interestingly, a kinase dead WNK3 model is a strong NCC inhibitor, demonstrating a 
dominant negative mechanism where the absence of WNK3 has an opposing effect [47,50]. WNK4 is 
necessary for phosphorylation and activation of NCC in in vivo mice studies via SPAK. When WNK4 
was inactivated, NCC expression and activity significantly reduced and a hypokalaemic metabolic 
alkalosis developed and angiotensin II no longer phosphorylated SPAK and NCC. The opposite 
occurred when WNK4 was overexpressed in murine models, which resulted in reduced blood 
pressure, hypokalaemia, and hypocalciuria, essentially a Gitelman phenotype [51]. In contrast, other 
transgenic murine studies where WNK4 was significantly overexpressed (two-fold higher levels of 
WNK4 kidney protein) produced increased phosphorylation of OSR1, SPAK, and NCC in the kidney, 
leading to a Gordon syndrome phenotype [52]. Clearly there is a balance of WNK4 protein levels 
required for physiological NCC regulation (see Figure 2). 
More recently, a deeper understanding of the WNK pathway’s involvement in ion transport has 
uncovered an additional mechanism for the generation of hyperkalaemia and metabolic acidosis in 
Gordon syndrome. WNK4 has been shown to significantly inhibit Maxi-K channel (BK) activity and 
expression in a kinase-dependent manner. This is done via lysosomal degradation rather than 
clathrin-dependent endocytosis as WNKs do with other membrane proteins. This demonstrates a 
broader role of WNK4 in potassium homeostasis [53]. Mice transgenic for a WNK4 missense mutation 
(TgWnk4PHA2) seen in Gordon syndrome show activation of Pendrin activity (an anion exchange 
protein encoded by SLC26A4), suggesting WNK4 is involved in Pendrin activation [53]. This theory 
has also been suggested in other studies [54,55]. Pendrin has been shown to work in concert with 
NCC to favour electroneutral NaCl reabsorption in distal nephron at the expense of ENaC suggesting 
that disordered regulation of Pendrin is also involved in the generation of hyperkalaemia in Gordon 
syndrome [56–61]. This is also validated in that decreased urinary potassium secretion in TgWnk4PHA2 
mice is reversed by Pendrin deletion. When Pendrin is genetically ablated in TgWnk4PHA2 mice, 
hyperkalaemia resolves and this could be due to enhanced BK activity in intercalated cells as the BK-
β-4 subunit is present in intercalated cells with the BK-α subunit in addition to L-WNK1, which 
activates BK [62]. Pendrin also has a role in the generation of metabolic acidosis in Gordon syndrome. 
Pendrin-mediated cellular Cl−/HCO3− exchange and number of Pendrin-expressing cells significantly 
increase and genetic ablation of Pendrin completely corrects metabolic acidosis in TgWnk4PHA2 mice. 
This suggests that metabolic acidosis is, in fact, likely to be caused by distal nephron bicarbonate 
wasting in Gordon syndrome [63]. 
WNK4 has been shown to be regulated by various other molecules that clearly influence WNK 
signalling. Osmotic stress and hypotonic low-chloride stimulation increase WNK4 Ser575 
phosphorylation via the p38MAPK-MK pathway, suggesting that this pathway might regulate 
WNK4 in an osmotic stress-dependent manner [64]. Other molecules that have been shown to 
stimulate elements of the WNK-SPAK pathway include aldosterone, angiotensin II, vasopressin, 
norepinephrine, insulin, and parathyroid hormone. Glucocorticoids, estrogen, progesterone, and 
prolactin certainly have a stimulatory effect on NCC; however, their exact mechanisms are currently 
unknown [65]. Interestingly, the extensively used organ transplant immunosuppressant, Ciclosporin, 
alters the WNK signalling pathway, and can cause hypertension, hyperkalaemia, and metabolic 
acidosis [66]. Another calcineurin inhibitor, Tacrolimus, also impairs NCC dephosphorylation, 
stimulating NCC [67]. The chemotherapeutic agent, Cisplatin, has an inhibitory effect on NCC by 
reducing NCC mRNA expression [68]. 
Genes 2019, 10, 986 7 of 18 
 
 
Figure 2. Regulation of NCC by WNKs. 
Wild-type WNK4 phosphorylates and activates NCC via SPAK activation and mutant WNK4 
further phosphorylates and activates WNK4 in a SPAK-dependent manner [51]. Wild-type WNK3 has 
a more modest effect on NCC. WNK3 phosphorylates and activates NCC via SPAK and this is only 
done in a kinase-dependent manner. Kinase-dead WNK3 acts in the opposite way and inhibits NCC 
[47–50]. Wild-type L-WNK1 phosphorylates NCC via SPAK and this pathway is exaggerated in 
mutant WNK1 models even in the absence of WNK4 [33,45]. 
4. Discovery of SPAK and OSR1 
Further research into the WNK signal transduction pathway revealed two new molecules 
important in the pathway involving WNK isoforms and their role in blood pressure and electrolyte 
homeostasis: SPS1-related proline/alanine-rich kinase (SPAK) and oxidative stress-responsive kinase 
(OSR1). SPAK was initially identified as a novel kinase in a pancreatic β-cell PCR screen [69] and 
OSR1 was discovered in sequencing a large DNA region of human chromosome 3 during a search 
for tumour suppressor genes [70]. Phylogenetic tree analysis of all human kinase domains placed the 
WNK family closest to the STE20 protein kinase family, which includes SPAK and OSR, hinting that 
these kinases interact in some way [71]. Further work demonstrated that SPAK and OSR also interact 
with the aforementioned CCC membrane-associated proteins. These included KCC (K-Cl co-
transporter), NKCC1 (Na-K-2Cl cotransporter), NKCC2, WNK4, and WNK1 with respect to SPAK 
and CLH3 (CIC-type chloride channel); and WNK1, WNK2, and WNK4 for OSR1 [41,72–75]. WNKs 
phosphorylate and activate SPAK and OSR1, which subsequently phosphorylate the CCCs [31]. 
SPAK has three isoforms and FL-SPAK (full length) and KS-SPAK (kidney specific) have been seen 
to co-localize with NCC at the DCT and NKCC2 in the TAL, respectively, in immunofluorescence 
studies [73,76]. Shorter SPAK isoforms might have an inhibitory effect on NKCC2 as SPAK knock-
out mice had an increase in NKCC2 activity and phosphorylation whilst this was reduced in SPAK 
knock-in mutants. Clearly, OSR1 does not compensate enough for the absence of SPAK in these 
models [77]. When OSR1 is inactivated, a phenotype similar to Bartter syndrome develops due to 
reduced phosphorylation and activation of NKCC2. Interestingly, when a double SPAK-OSR1 knock-
out mouse was analysed, these was still significant phosphorylation of NKCC2, suggesting a third 
kinase is involved in this cascade [77]. Various mouse models have been created to assess the role of 
SPAK. In every model with defective or absent SPAK, NCC phosphorylation is substantially reduced 
and a Gitelman syndrome phenotype is observed, which demonstrates the importance of SPAK and 
OSR1 in the WNK cascade of CCC, especially NCC and NKCC2, activation [76–78]. 
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More recently, several studies have demonstrated that the WNK-SPAK/OSR1 pathway 
components concentrate into large WNK bodies at discrete foci in the DCT in response to potassium 
balance changes. For example, during hypokalaemia, the diffuse distribution of WNK, SPAK, and 
OSR1 transition to form a punctate presence in the DCT, which have been seen in genetically 
modified mice [79]. When total body potassium balance is altered via dietary or genetic manipulation 
to the WNK-SPAK/OSR1 pathway, these puncta are exclusively present in this environment and 
almost entirely limited to the DCT and have been shown to require KS-WNK1 for their expression 
[76,80–83]. WNK1 forms DCT-specific particles during potassium loading or restriction. This ‘renal 
potassium switch’ has become fundamental in our understanding of the role of potassium intake in 
the development of hypertension via the WNK-SPAK-NCC pathway. For example, low potassium 
intake induces hyperpolarization of the early DCT cell membrane, which favours Cl- efflux across the 
basolateral membrane and decreases intracellular Cl- concentration and activates WNK-SPAK 
signalling. WNK4 forms heterodimers with ks-WNK1 and assembles with ribosomal protein 22 sub 
nuclear puncta and causes SPAK-induced NCC phosphorylation [64]. This WNK-WNK reaction 
requires a cysteine-rich hydrophobic motif within a unique N-terminal exon of KS-WNK4 and these 
WNK-WNK assemblies require aldosterone in high potassium environments [66,67]. 
Kidney-specific SPAK is highly abundant along the thick ascending loop of Henle (TAL) 
whereas full-length SPAK is more abundant along the DCT. SPAK knock-out animals show increased 
phosphorylation of NKCC2 in the TAL and decreased phosphorylation in the DCT. In mice, 
extracellular fluid depletion influences SPAK abundance to favour NaCl retention along both 
segments, which indicates that a SPAK isoform switch modulates sodium control across the distal 
nephron [78]. Mouse models confirm that OSR1 mainly activates NKCC2-mediated sodium transport 
along the TAL while SPAK mainly activates NCC along the DCT, but the kinases compensate for 
each other [84]. 
5. Mechanisms of Hyperkalaemia in Gordon Syndrome 
Understanding the ion transport protein pattern is important to be able to understand how the 
WNK kinases, Kelch-like 3 and Cullin 3, regulate electrolyte homeostasis. Three views on the 
mechanism of hyperkalaemia in Gordon syndrome currently exist: Direct reduction on K+ secretion 
(theory one), a secondary deficiency in K+ secretion due to lack of chloride (Cl−) reaching ENaC 
(theory two), and lack of Na+ reaching ENaC for adequate exchange with K+ (theory three). Potassium 
is secreted mostly via ROMK channels so it would be expected that these channels would be depleted 
in Gordon syndrome. Chloride reabsorption via the paracellular pathways (including claudin 
channels) is increased, resulting in less negativity at the ENaC and subsequent depression of the 
ROMK transporter. Therefore, the chloride shunt would be increased in Gordon syndrome. This 
chloride shunt theory was that pre-treatment with mineralocorticoid, intravenous Na2SO4, and 
NaHCO3 could cause increased potassium excretion in Gordon syndrome but that sodium chloride 
was less able to do so. A chloride shunt proximal to the ENaC would result in less chloride delivery 
and subsequently less ENaC negativity, which would result in decreased potassium secretion [4]. 
Other studies have reinforced this theory, but mathematical modelling of the DCT does not 
demonstrate the need of this theory to explain Gordon syndrome. Finally, increased NCC activity 
results in a reduction in Na+ reaching ENaC for reabsorption, thereby depressing its action and 
resulting in hyperkalaemia. Figure 3 summarises the mechanisms of potassium homeostasis 
involving WNK-kinases and the impact of WNK-kinases on each of these protein transporters will 
now be discussed. 
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Figure 3. Mechanisms of potassium homeostasis in the β-intercalated and principal cells of the 
collecting duct. 
The impact of wild-type WNK4 and wild-type WNK1 on five tubular channels are demonstrated. 
Red arrows represent inhibitory effects and green arrows represent stimulatory effects. WNK4 causes 
increased paracellular chloride channel (claudin channel) permeability, which is exacerbated by 
mutant WNK4 [34]. WNK4 also inhibits the epithelial sodium channel (ENaC) by stimulating 
glucocorticoid-induced kinase 1 and the opposite is true for mutant WNK4 [31,85]. WNK4 reduces 
plasma membrane renal outer medullary potassium channel (ROMK) and maxi-K channel (BK) 
abundance and these inhibitory effects are markedly increased by mutant WNK4 [34,53]. WNK1 
stimulates ENaC via phosphatidylinositol 3-kinase and it stimulates BK expression. As mutant 
WNK1 increases WNK1 expression, ENaC and BK stimulation are exaggerated in Gordon syndrome 
[33,86–88]. WNK1 inhibits ROMK activity and therefore its inhibition is also exaggerated by mutant 
WNK1 [89]. KS-WNK1 stimulates ENaC and inhibits WNK1′s stimulation of the same channel and 
its inhibition of ROMK [88,90,91]. Wild-type WNK4 regulates Pendrin, but mutant WNK4 stimulates 
Pendrin activity and surface expression [56–61]. 
5.1. Lack of Na+ Reaching ENaC for Adequate Exchange with K+ 
WNK1 has been found to increase the activity of ENaC by activating phosphatidylinositol 3-
kinase, which stimulates glucocorticoid-induced kinase 1 (a well-known ENaC-regulatory factor). 
Interestingly, this effect of WNK1 on ENaC depends on an intact WNK1 kinase domain but also 
requires an intact amino acid terminal domain (N-terminal of the kinase domain), but KS-WNK1 
(kidney specific) also stimulates ENaC without both of these domains [33,86–88]. This implies a 
different ENaC-stimulating mechanism between WNK1 and KS-WNK1. WNK4 does the opposite to 
ENaC activity; WNK4 stimulates glucocorticoid-induced kinase 1, which inhibits ENaC. When 
expressed in Xenopus oocytes and in mice, ENaC activity is not inhibited by the Gordon syndrome 
mutant WNK4 and subsequent increased ENaC activity is seen in the kidney and colon in these 
mutant models [31,85]. Now that ENaC involvement has been established, three observations justify 
why more than just ENaC is involved in the pathogenesis of Gordon syndrome. Firstly, thiazide 
diuretics correct both hyperkalaemia and hypertension in patients with Gordon syndrome, including 
in patients who have WNK4 mutations and animal models with mutant Wnk4. Thiazide diuretics 
affect NCC and do not directly affect ENaC but do increase distal Na+ delivery where ENaC 
expression is abundant. Second, the increased ENaC activity in WNK4 D561A knock-in animals can 
be reversed with thiazide diuretics, which suggests that these effects on ENaC are not directly from 
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WNK kinases; they must be secondary physiological effects. Finally, ENaC stimulation should result 
in hypokalaemia, not the hyperkalaemia we see in Gordon syndrome. 
5.2. Direct Reduction on K+ Secretion 
WNK4 reduces plasma membrane ROMK abundance in the distal nephron and inhibits, through 
a kinase-independent mechanism, ROMK activity in vitro [85,90]. Its effects on ROMK are dependent 
on dynamin and involves clathrin-medicated endocytosis, which is not the case when compared with 
the WNK4 effect on NCC [92]. WNK1 inhibits ROMK as well but whether this depends on intact 
kinase activity is in conflict and this is done by dynamin-dependent endocytosis [89]. KS-WNK1 does 
not have a direct effect on ROMK, but it does block the effects of WNK1 on this channel in addition 
to inhibiting NCC [90,91]. It has been shown that mutant WNK4 additionally inhibits ROMK in 
comparison to wild-type WNK4, so this effect is more powerful, resulting in a reduced plasma 
membrane ROMK abundance [86]. Again, as for ENaC, now that we have established ROMK 
involvement in Gordon syndrome, it is clear that ROMK cannot be the only channel affected in 
Gordon syndrome due to the following three reasons. Firstly, treatment with a thiazide diuretic 
would not be expected to correct an ROMK defect [93,94], yet it corrects hyperkalaemia in Gordon 
syndrome. However, you would expect urinary sodium and water excretion to increase with thiazide 
diuretic use due to distal flow stimulating potassium secretion but serum potassium is lowered, 
despite urinary Na and water remaining unchanged, from baseline in Gordon syndrome subjects, 
suggesting further distal alternative channel involvement. Secondly, when non-chloride Na+ salts are 
infused in Gordon syndrome subjects, normal amounts of potassium are excreted, demonstrating 
intact potassium secretory apparatus and that, in Gordon syndrome, impaired potassium secretion 
is a result of the reduced (aldosterone sensitive) distal nephron voltage [4,95]. Thirdly, mutant WNK4 
transgenic animals do not appear to have a difference in ROMK abundance [93,94]. 
5.3. A Secondary Deficiency in K+ Secretion Due to Lack of Chloride Reaching ENaC 
A distal nephron chloride shunt is also proposed as a mechanism of hyperkalaemia in Gordon 
syndrome. It has been suggested that an increased permeability of paracellular chloride channels in 
the distal nephron results in increased Cl- reabsorption and a subsequently less negative gradient at 
ENaC, so it is depressed. ENaC depression results in decreased Na+ reabsorption and reduced 
potassium secretion, causing hypertension and hyperkalaemia [4]. Evidence that WNK4 is involved 
in this process is supported in various ways. WNK4 has been observed to colocalize with tight 
junctions where the paracellular chloride channels are [96]. Furthermore, when overexpressed in 
culture cells, WNK4 has been shown to affect paracellular chloride permeability [34]. Also, mutant 
WNK4 increased chloride permeability when compared to Na+ permeability and this required 
catalytic activity of WNK4 (WNK4 phosphorylated claudins 1–4 and kinase-inactive WNK4 did not 
affect chloride channel permeability) [34]. However, as with the other channels, the ability of a 
thiazide diuretic alone to correct the hyperkalaemia is not consistent with dominant chloride channel 
involvement in Gordon syndrome as this directly interacts with NCC and has never been seen to alter 
the paracellular chloride channels. A further argument against chloride channel involvement is that 
WNK4 D561A knock-in mice show no difference in the measurement of paracellular permeability 
when compared with wild-type collecting ducts [94]. 
6. The Role of Kelch-like 3 and Cullin 3 
More recently, mutations in two further genes have been identified, KLHL3 and CUL3, which 
account for 80% of families with Gordon syndrome [15,97]. KLHL3 mutations can be dominant or 
recessive whilst CUL3 mutations are usually dominant or de novo [15]. Kelch-like 3 (encoded from 
KLHL3) contains three domains: A BACK domain, an N-terminal BTB domain, and a six-bladed β-
propeller structure formed from Kelch-like repeats [98,99]. These Kelch propeller domains bind 
substrate proteins so that they can be ubiquitinated via their interaction with the BTB domain of 
Cullin 3 (encoded from CUL3). This interaction is termed the CUL3-KLHL3 E3 ligase complex (a ring-
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like complex) [99–101]. Ubiquitination via this complex not only targets proteins for degradation but 
also modulates protein activity, localisation, and interaction [102,103]. Kelch-like 3 is predominantly 
expressed in the apical DCT and collecting duct whilst Cullin 3 is expressed across all segments of 
the nephron, especially in the proximal tubule, when stained in mice kidneys [97]. This initially 
demonstrated the role of this complex in distal nephron electrolyte homeostasis. 
Immunoprecipitation of Kelch-like 3 demonstrated its strong association with WNK isoforms in 
addition to Cullin 3. In total, 13 out of 15 dominant KLHL3 mutations inhibited the binding of Kelch-
like 3 to WNK1 or Cullin 3 and when studies were performed in vitro, the recombinant wild-type 
CUL3-KLHL3 E3 ligase complex (but not the disease causing complex) ubiquitinated WNK1 [102]. 
Furthermore, siRNA-mediated CUL3 knockdown increased WNK1 levels and its kinase activity in 
HeLa cells [103]. The KLHL3 interaction site in WNK1 is on a non-catalytic region, which is 
interestingly the equivalent site on WNK4, which encompasses mutated residues in Gordon 
syndrome patients. WNK4 mutations (E562K and Q565E) and an equivalent WNK1 fragment 
mutation (479–667), a deletion, prevents their ability to interact with Kelch-like 3 [103]. Knock-in mice 
carrying KLHL3 disease causing mutations exhibited salt-sensitive hypertension, hyperkalaemia, and 
metabolic acidosis and revealed that both WNK1 and WNK4 were increased within the kidney due 
to impaired KLHL3-Cullin 3-mediated ubiquitination [104] Homozygous knockout KLHL3 mice 
models also produced a Gordon syndrome phenotype with increased WNK1 and WNK4 levels in the 
kidney [105]. All of this provides strong evidence that the CUL3-KLHL3 E3 ligase complex regulates 
blood pressure via its ability to ubiquitinate WNK isoforms and that Gordon syndrome results in 
mutations that disrupt the formation of this complex’s ability to prevent WNK degradation and 
therefore stimulate renal salt retention by increased activation of NCC and NKCC2 by WNK isoforms 
in excess. Figure 4 summarises the pathogenic effects of WNK4, KLHL3, and CUL3 mutations. 
When Gordon syndrome-causing KLHL3 mutations are examined, it is clear that they affect the 
binding of Kelch-like 3 with the acidic motif on WNK4-kinase in different ways. This is either by 
altering the electrostatic potential of the acidic domain-binding site or by disrupting the Kelch-like 3-
acidic motif hydrogen bonds. Mutations buried inside the Kelch-like 3 domain either have little or no 
impact on the interaction, suggesting that some buried mutations probably disrupt the Kelch-like 3-
acidic motif interaction by a different mechanism [106]. A Gordon syndrome mouse model has also 
been created with a Klhl3 mutation in the BTB domain, which should aid a better understanding of 
the Kelch-like 3/Cullin 3 interaction and contribute to possible future novel antihypertensive drug 
targets [107]. 
Kelch-like 3 is highly expressed along the DCT and substantially expressed along the TAL and 
collecting duct. However, Cullin 3 is uniformly expressed along all nephron segments except for the 
glomerulus, with the highest levels in the proximal convoluted tubule [108,109]. The DCT is highly 
sensitive to Gordon syndrome mutations in CUL3 because of the extremely high Kelch-like 3 
expression there. The proportional reduction in Kelch-like 3 levels have significant consequences on 
ion transport in the DCT in comparison to other segments. CUL3 knock-out models show significant 
defects along all nephron segments and also resulted in reductions on other tubular proteins, such as 
AQP2 and NKCC2, which override increased NCC expression, so a phenotype of salt wasting and 
polyuria develops rather than Gordon syndrome [109]. Interestingly, KS-CUL3 mice develop 
interstitial inflammation and fibrosis, in addition to a similar fibrotic picture when CUL3 is deleted 
from the liver. Also, humans can develop papillary renal cell carcinoma with loss-of-function CUL3 
mutations. This shows that loss of CUL3 activity is detrimental to cells and that KS-CUL3 mice could 
be a good candidate for experimental studies to slow CKD progression with CUL3 activating 
molecules [109]. 
The phenotypic severity of Gordon syndrome varies according to different causative mutations 
(CUL3 > recessive KLHL3 > dominant KLHL3 > WNK4 > WNK1) [97]. Gordon syndrome subjects with 
CUL3 mutations have the most severe phenotype and present at a younger age and had more severe 
hyperkalaemia, hypertension, and metabolic acidosis in addition to growth impairment. As many of 
these subjects had de novo CUL3 mutations, impairment of reproductive fitness is likely [97]. 
Recently, the severe phenotype of CUL3 mutations has been explained by the mutation’s effect on 
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vascular function in addition to renal. Activation of RhoA, a key regulator of vascular tone, was 
shown in mutant Cul3 mouse models in addition to acute blood pressure sensitivity to calcium 
channel blockers (Amlodipine) and altered aorta reactivity to phenylephrine and acetylcholine [110]. 
 
Figure 4. Summary of pathophysiology of Gordon syndrome in a tubular cell representative of 
different parts of the nephron. 
In wild-type conditions (left panel), WNK4 can stimulate NCC trafficking to the plasma 
membrane of the DCT and its activation is achieved by phosphorylation of NCC by SPAK/OSR1, 
stimulating NaCl transport. WNK1 and WNK4 can be ubiquitinated by Kelch-like 3 and Cullin 3. 
WNK4 is inhibited by WNK1. WNK1 also acts via SPAK and increases the phosphorylation of NCC. 
In Gordon syndrome (right panel), the pink arrows represent an increased abundance of mutant 
WNK1 and wild-type WNK1 and WNK4 and the green arrows (marked +) indicate increased 
expression of NCC on the apical membrane of the distal convoluted tubule (DCT), NKCC1 on the 
basolateral membrane of the collecting duct (CD), and NKCC2 on the apical membrane of the thick 
ascending loop of Henle (TAL). The red crosses signify the inability of WNK4 to bind with the Cullin 
3-RING ubiquitin ligase complex. Mutant WNK4 overstimulates plasma membrane proteins NCC, 
NKCC1, and NKCC2 because mutant WNK4 is unable to bind and be ubiquitinated by Kelch-like 3 
and Cullin 3; mutations in Kelch-like-3 or Cullin 3 lead to WNK1 and WNK4 accumulation because 
of a failure of the Cullin 3-RING ubiquitin ligase complex to form and ubiquitinate WNK [9,103]. 
Wild-type and mutant WNK4 phosphorylates SPAK and OSR1 to activate NCC, NKCC1, and 
NKCC2. Mutations in WNK1 are intronic deletions and do not affect the protein structure but lead to 
changes in the expression of a WNK1 isoform, which can phosphorylate and stimulate NCC. 
7. Conclusions 
By studying monogenic forms of hypertension, such as Gordon syndrome, new molecular 
pathways that regulate blood pressure and electrolyte homeostasis have been discovered. Not only 
will this prove helpful for the development of new drug targets for hypertension, one of the leading 
causes of cardiovascular disease, but it may help us to identify and categorise new subgroups of 
patients with hypertension based on genotype–phenotype correlations. In the future, more bespoke 
anti-hypertensive treatment will hopefully become a reality because of a deeper understanding of the 
physiology of blood pressure regulation in the kidney. 
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